Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

Cefepime-taniborbactam has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation by the U.S. Food and Drug Administration (FDA). In October 2022, BARDA awarded a contract ...

Tolerability of dronabinol alone, ondansetron alone and the combination of dronabinol plus ondansetron in delayed chemotherapy-induced nausea and vomiting No significant financial relationships to ...

intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...

Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 BARDA extends cost-sharing contract to ...

About The Study: Among 2,511 adults hospitalized with acute infection, treatment with the antibiotic piperacillin-tazobactam did not increase the incidence of acute kidney injury or death in this ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review was ...

In patients with complicated urinary tract infection, clinical and microbiologic treatment success was significantly better with cefepime–taniborbactam (β-lactam and β-lactamase inhibitor) than with ...

Mortality associated with cefepime (Maxipime) was evaluated in a systematic review and meta-analysis of 57 randomized trials comparing cefepime with another beta-lactam antibiotic; the review was ...

For complicated urinary tract infection, the efficacy and safety of the investigational cefepime–taniborbactam combination, in comparison with standard treatment with meropenem, are unknown. New ...